Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,108 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The EMA assessment of pembrolizumab as monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.
Trullas A, Delgado J, Genazzani A, Mueller-Berghaus J, Migali C, Müller-Egert S, Zander H, Enzmann H, Pignatti F. Trullas A, et al. Among authors: delgado j. ESMO Open. 2021 Jun;6(3):100145. doi: 10.1016/j.esmoop.2021.100145. Epub 2021 Apr 30. ESMO Open. 2021. PMID: 33940347 Free PMC article. Review.
EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K, Penttilä K, Lähteenvuo J, Lapveteläinen T, Lopez Anglada L, Prieto C, Garcia-Ochoa B, Enzmann H, Gisselbrecht C, Delgado J, Pignatti F. Tzogani K, et al. Among authors: delgado j. Oncologist. 2021 Jan;26(1):70-76. doi: 10.1002/onco.13592. Epub 2020 Nov 23. Oncologist. 2021. PMID: 33179377 Free PMC article. Clinical Trial.
The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors.
Araujo-Fernandez I, Delgado J, Moscetti L, Sarac SB, Zander H, Mueller-Egert S, Dunder K, Pean E, Bergmann L, Enzmann H, Pignatti F. Araujo-Fernandez I, et al. Among authors: delgado j. ESMO Open. 2021 Feb;6(1):100008. doi: 10.1016/j.esmoop.2020.100008. Epub 2020 Dec 16. ESMO Open. 2021. PMID: 33399074 Free PMC article. Review.
The EMA assessment of encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal carcinoma harbouring the BRAFV600E mutation who have received prior therapy.
Trullas A, Delgado J, Koenig J, Fuerstenau U, Dedorath J, Hausmann S, Stock T, Enzmann H, Pignatti F. Trullas A, et al. Among authors: delgado j. ESMO Open. 2021 Feb;6(1):100031. doi: 10.1016/j.esmoop.2020.100031. Epub 2021 Jan 8. ESMO Open. 2021. PMID: 33422765 Free PMC article. Review.
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F. Delgado J, et al. ESMO Open. 2021 Apr;6(2):100087. doi: 10.1016/j.esmoop.2021.100087. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33735800 Free PMC article. Review.
The EMA assessment of avapritinib in the treatment of gastrointestinal stromal tumours harbouring the PDGFRA D842V mutation.
Trullas-Jimeno A, Delgado J, Garcia-Ochoa B, Wang I, Sancho-Lopez A, Payares-Herrera C, Dalhus ML, Strøm BO, Egeland EJ, Enzmann H, Pignatti F. Trullas-Jimeno A, et al. Among authors: delgado j. ESMO Open. 2021 Jun;6(3):100159. doi: 10.1016/j.esmoop.2021.100159. Epub 2021 May 20. ESMO Open. 2021. PMID: 34023541 Free PMC article. Review.
2,108 results